Kliničke studije za Limfom u državi Arizona
11 studija za Limfom traži sudionike na lokacijama u državi Arizona.
Gradovi u državi Arizona
Službeni tekst studije (engleski)
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Banner MD Anderson Cancer Center, Phoenix
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 17. ruj 2026. · NCT07221500CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Phoenix Childrens Hospital, Phoenix
U tijeku regrutacijaFaza 1/2
12 Months – 21 Years · Oba spola · Ažurirano 11. ruj 2026. · NCT04870944Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope - Phoenix, Goodyear
- Mayo Clinic, Phoenix
- Honor Health, Scottsdale
U tijeku regrutacijaFaza 1/2
Od 12 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT04588922A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Banner MD Anderson Cancer Center, Gilbert
- Honor Health, Scottsdale
- Mayo Clinic Arizona, Scottsdale
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 4. kol 2026. · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Banner MD Anderson Cancer Center, Gilbert
- Mayo Clinic, Phoenix
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 13. srp 2026. · NCT04792489Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
- The University of Arizona, Tucson
U tijeku regrutacijaRana faza 1Zdravi dobrovoljci dobrodošli
Od 21 do 55 godina · Oba spola · Ažurirano 5. lip 2026. · NCT06643221Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Phoenix Childrens Hospital, Phoenix
- Banner University Medical Center - Tucson, Tucson
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 18. svi 2026. · NCT01790152CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- St. Joseph's Hospital and Medical Center, Phoenix
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 16. tra 2026. · NCT03328078A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
- City of Hope Phoenix, Goodyear
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 27. ožu 2026. · NCT06915246BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
- Mayo Clinic Arizona, Phoenix
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 20. velj 2026. · NCT06854003Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- Mayo Clinic Arizona, Scottsdale
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2025. · NCT04234048Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.